GSK Phase II Win Offers Hope For TB Breakthrough

Second Antibiotics Success For UK Major This Month

16 Nov 2022

Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.

GSK plc has raised hopes of an improved treatment option for tuberculosis (TB), the world's biggest infectious disease killer over the last decade, after posting promising mid-stage data on a first-in-class investigational antitubercular agent.

The UK major has announced positive results from a Phase IIa study demonstrating that the therapy, codenamed GSK3036656, was well...